Atogepant (Qulipta)


 CADTH recommends that Qulipta be reimbursed by public drug plans for the prevention of episodic migraine, if certain conditions are met.
 should only adults with according to criteria used other calcitonin gene-related peptide (CGRP) inhibitors migraine.
 In addition following pre-existing CGRP inhibitors, not in combination inhibitors. cost is reduced such total treatment does exceed least costly inhibitor preventive migraine adults.